Breaking News Could Draw Serious Buzz To (BSEM) After Announcing A New Product Line Launch

BioStem Technologies, Inc. (BSEM) just dropped breaking news this morning.

*Sponsored Breaking News Could Draw Serious Buzz To (BSEM) After Announcing A New Product Line Launch *Get Our Updates Faster—Tap Here To Receive SMS Alerts* December 10th Greetings, Friend! BioStem Technologies, Inc. (BSEM) just dropped breaking news this morning. Check it out: BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference Expanding its Portfolio with American Amnion to Serve the Wound Care Needs of Our Veterans POMPANO BEACH, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company specializing in placental-derived biologics for advanced wound care, today announced the launch of a new product line, American Amnion, at the Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference held in Phoenix, Arizona, on December 10-13, 2025. American Amnion AC is a human connective tissue allograft comprised of full thickness dehydrated human amnion and chorion membrane (DHACM) including the intermediate layer, while American Amnion is comprised of dehydrated human amnion membrane (DHAM) also including the intermediate layer. Both are intended for homologous use as a protective covering for acute or chronic wounds and are produced using BioStem’s proprietary BioRetain® technology, which optimizes the preservation of the native tissue’s innate structural and molecular composition. Allografts produced with this technology have demonstrated superior clinical performance as documented in several recently published studies. In a multi-center randomized controlled clinical trial published in the International Journal of Tissue Repair (2025), McCoy et al. reported that patients treated with the BioRetain-preserved full thickness amniochorion product (referenced in the published manuscript as BR-AC) demonstrated a probability of wound closure (53%) that was almost twice that observed in patients treated with the standard of care (31%). Similarly, in a comparative retrospective study published in Health Science Reports (2024), Frykberg et al. documented that the BioRetain-preserved DHACM outperformed a leading competitor in both clinical and cost effectiveness, by demonstrating a 14% reduction in time to closure and requiring 27% fewer applications to achieve closure. “Veterans represent a significantly underserved population with a disproportionately high risk of chronic, non-healing wounds. The introduction of American Amnion is a meaningful step forward in advancing the standard of care for these patients,” said Jason Matuszewski, CEO and Chairman of BioStem Technologies. “The use of placental-based products has increased by 50% over the last five years in the VA system. By bringing innovative, evidence-driven solutions to market, we are not only improving outcomes and quality of life for our veterans, but also helping our clinician partners deliver more efficient, cost-effective care.” ... Read the full article here. Remember. BSEM is a low float idea. With roughly 6.82Mn shares in its float, the potential for heightened volatility could be high after today's news. Take a moment to review my initial (BSEM) report below and consider this profile for your watchlist. ----- A fast-moving player in the regenerative sciences space is quietly making headway in regenerative therapies designed to restore, repair, and revitalize human health. By combining advanced biotechnology with proprietary clinical insights, the organization is addressing some of the most persistent challenges in tissue restoration and long-term recovery. Recent developments suggest meaningful traction in areas that could transform how the body heals itself—naturally and effectively. For those tracking health innovation at the cellular level, this company’s approach deserves a closer look before its broader story reaches the spotlight. And with a low float, strong analyst target, a major development with Florida Medicaid, and strong top-line results, this under-the-radar profile tops my watchlist Wednesday: BioStem Technologies, Inc. (BSEM) BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture and commercialization of allografts for regenerative therapies. The company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. Multi-Bn Dollar Market Opportunity Chronic Non-healing Wounds Impact Millions of Patients Annually PU, DFU and VLU represent 82% of chronic wounds • Wound Care Market data from SmartTrak Q424/FY24 Advanced Wound Care Market report, May 2025 Sites of Care for Wound Treatment BioStem plans to expand focus beyond Mobile Health and Private Office into: Ambulatory Surgery Center (ASC) Hospital Outpatient Department (HOPD) Veteran Affairs (VA) BioREtain® - The Power Of Six The patented six-step BioREtain® process is gentle, minimally invasive, and preserves the natural integrity of the amniotic tissue/ components critical to the inherent wound healing process. *The company's sterilization assurance level (SAL) is generally accepted for pharmacopeial sterilization procedures, with a probability of not more than one viable microorganism per one million sterilized items of the final product. Commercial Portfolio - Powered by BioREtain® Discover Sources And More: BSEM Website. BSEM Presentation. ----- 5 Explosive Potential Catalysts Put (Nasdaq: BSEM) On Radar Watch #1. BSEM Has A Fairly Low Float (Volatility Potential Could Be Explosive). With a float of roughly 6.82Mn shares, according to the OTC Markets website, volatility potential could pop up in a flash. #2. A $25.50 Analyst Target Spells Triple-Digit Potential Upside For BSEM. Brad Sorensen of Zacks Small-Cap Research recently reiterated a $25.50 target for BSEM. From its closing valuation on Tuesday, this target suggests BSEM may have a potential 500+% upside. #3. BioStem Technologies Strengthens Access Through Expanded Medicaid Coverage Nationwide. BioStem Technologies achieved a major step forward as Florida Medicaid added VENDAJE® and VENDAJE AC® to its list of covered skin substitutes. This inclusion extends BioStem’s advanced wound care access to thirteen Medicaid programs nationwide, reinforcing the company’s mission of delivering high-quality, evidence-based healing solutions. CEO Jason Matuszewski believes that Florida’s large Medicaid market will greatly expand BioStem’s patient reach. The move validates the clinical and economic value of its technology and positions Medicaid expansion as a key long-term growth driver in the $11Bn U.S. wound care market. #4. BioStem Technologies Achieves Breakthrough Success With BioREtain® Clinical Trial Results. BioStem Technologies announced strong top-line results showing its BioREtain® allograft significantly outperformed standard care in treating diabetic foot ulcers. Published in the International Journal of Tissue Repair, the randomized trial revealed a 53% healing rate for BioREtain® versus 31% for standard treatment, nearly doubling the probability of lasting wound closure. Conducted under FDA-rigorous standards with hard-to-heal patients, the study validates BioREtain’s superior performance. CEO Jason Matuszewski emphasized the findings strengthen BioStem’s clinical credibility, encouraging broader adoption and commercial growth in advanced wound care solutions. #5. BioStem Technologies Expands Growth With New Boca Raton Headquarters Development. BioStem Technologies announced purchasing land at the Research Park at Florida Atlantic University in Boca Raton for its future headquarters, supported by up to $300k in city economic incentives. The 4-acre site will unite manufacturing, distribution, and administration, fostering growth and job creation while keeping the company rooted in South Florida. CEO Jason Matuszewski emphasized the decision reflects BioStem’s long-term commitment to innovation, collaboration, and local economic development. The new headquarters will position BioStem among leading technology innovators and strengthen South Florida’s growing life sciences ecosystem. ----- It's official. Coverage is now underway on BioStem Technologies, Inc. (BSEM) Keep your eyes peeled for updates coming shortly. Talk soon. All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 12/09/2025 and ending on 12/10/2025 to publicly disseminate information about (BSEM:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid six thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (BSEM:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/bsem-cxk09/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Update Profile | Our Privacy Policy | Constant Contact Data Notice